Bridging the Gap: The Crucial Role of Private Healthcare in Achieving Universal Health Coverage

By Staff Writer

September 1, 2023

The World Bank Group (2017) estimates that at least half of the world’s population lacks access to basic healthcare. Moreover, nearly 100 million people are plunged into poverty annually due to healthcare expenses. These gaps in health provision are notably severe in low-income countries (LICs), where the majority of those facing impoverishing health expenses reside.

Universal Health Coverage (UHC) – defined as the global aim to ensure everyone receives the health services they need without suffering financial hardship – has been proposed as a solution to this pressing issue. The World Health Organisation (WHO) conceptualizes UHC as a ‘cube’ comprising three key dimensions: population coverage, service coverage, and financial risk protection.


Source: Authors’ own elaboration, adapted from Kutsin (2013) and the WHO UHC cube (World Health Organisation, 2010; Kutzin, 2013).

However, the role of private healthcare in achieving UHC remains a subject of ongoing debate. While the public and private health sectors interact and shape each other’s performance, the unclear boundaries between the two make it difficult to define a UHC role for the private sector.

Private-for-profit (PFP) providers, motivated by commercial interests, and private not-for-profits (PNFPs), usually driven by philanthropic motives, are the two main types of private healthcare providers. The central role of profit in PFPs has ignited debate on their ability to adequately serve the poor and whether they can be contracted by governments to advance UHC goals.

The informal sector in LICs, which includes traditional birth attendants and healers, unlicensed drug shops, and market stalls, provides a substantial proportion of healthcare, particularly for the poor. However, the quality of care in both the public and private sectors in LICs often falls short, particularly at the lower end of the market.

A recent study extends the debate on the role of private healthcare in LICs by systematically reviewing recently published literature. They found that while formal private providers typically operate in already well-served urban settings, informal and not-for-profit ones cater to patients in underserved rural areas and generally at the lower end of the health market.

However, improving the quality and financing of informal providers may be key to expanding UHC in LICs. Given their ubiquitous nature and diversity of contributions, mechanisms for (self) accreditation will need to be strengthened to guarantee a minimum level of service quality from these actors.

Quality and effectiveness should be considered core principles of universal coverage and represent an additional dimension of the UHC cube in its own right.

Reference url

Recent Posts

NICE health technology evaluations
        

Evolving NICE Health Technology Evaluations: Enhancing Patient Perspectives and Addressing Health Inequalities

🌟 Are you ready to embrace a new era in health technology evaluations?

Our latest article dives into the recent updates from NICE regarding the incorporation of patient perspectives and tackling health inequalities in their health technology assessments. By exploring stakeholder feedback and proposed methodologies, we uncover a shift towards more inclusive and transparent evaluations that could reshape market access and reimbursement policies in the UK healthcare system.

Don’t miss out on these vital insights that could impact your understanding of healthcare value! Read the full article [here](https://www.nice.org.uk/process/pmg36/documents/consultation-comments-and-responses).

#SyenzaNews #HealthEconomics #MarketAccess

Canada Drug Agency Plan
          

Canada Drug Agency Plan: Shaping the Future of Health Systems 2025-2030

🚀 Are you ready to explore the future of healthcare in Canada?

The newly launched **Canada Drug Agency Plan** aims to redefine how we approach drug and health technology decisions, focusing on anticipation, innovation, and transformation to boost health outcomes for all Canadians. This five-year strategic initiative captures essential insights needed for a healthier nation amid evolving pharmaceutical policies.

Curious how this plan could impact the healthcare landscape? Dive into the full article to learn more!

#SyenzaNews #HealthcarePolicy #HealthTech #Innovation

hepatitis C treatment options
       

VIETNARMS Trial Unveils Innovative Hepatitis C Treatment Options

🔍 Are you curious about the latest advancements in hepatitis C treatment options?

The groundbreaking VIETNARMS trial reveals that sofosbuvir-daclatasvir offers a comparable efficacy to sofosbuvir-velpatasvir while exploring innovative strategies that could reshape treatment accessibility and affordability. With cure rates exceeding 90%, these findings hold promise for improving outcomes, especially in underserved populations.

Dive into the full article to uncover how these developments could revolutionize hepatitis C care!

#SyenzaNews #globalhealth #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.